医学
再狭窄
含氟聚合物
外科
狭窄
支架
冲程(发动机)
入射(几何)
随机对照试验
血管成形术
血管内治疗
内科学
血管疾病
前瞻性队列研究
临床试验
并发症
神经学
放射科
裸金属
回顾性队列研究
临床终点
药物洗脱支架
作者
Ying Yu,Xuan Wang,Liangfu Zhu,Chengbo Dai,Weisheng Deng,Yunfeng Zhang,J K Han,Han Jl,Liping Wei,Jianglong Tu,Xinguang Yang,Jieqing Wan,Congguo Yin,Hongchao Shi,Jinglin Yuan,Liyu Wang,Chun Chen,Weilun Fu,Baixue Jia,Zhikai Hou
标识
DOI:10.1136/jnnp-2026-338887
摘要
BACKGROUND: The high incidence of in-stent restenosis (ISR) associated with bare-metal stents (BMS) undermines the viability of endovascular treatment as a treatment option for patients with severe symptomatic intracranial atherosclerotic stenosis (ICAS). The study aimed to evaluate whether durable fluoropolymer drug-eluting stents (DES) reduce the incidence of ISR compared with BMS in the treatment of severe ICAS. METHODS: This prospective, multicentre, open-label, blinded outcome clinical trial was conducted at 16 centres in China, enrolling patients with ischaemic stroke or transient ischaemic attack (<90 days) attributed to 70%-99% stenosis of an intracranial major artery. Eligible patients were randomly assigned to receive durable fluoropolymer DES or BMS for stenosis treatment. The primary outcome was ISR at 1 year postprocedure, which was defined as a stenosis rate of ≥50% occurring within or immediately adjacent to (within 5 mm) the stent. Secondary outcomes included symptomatic ISR and stroke or death within 30 days or stroke in the target vessel territory between 31 days and 1 year. RESULTS: Between 20 February 2023 and 10 April 2024, 156 patients were enrolled and assigned to receive DES (n=78) or BMS (n=78). The median age was 61 years (IQR 54-67), and 129 (82.7%) of 156 patients were male. At 1 year, the primary outcome occurred in 2.9% in the DES group versus 27.9% in the BMS group (risk difference -0.25, 95% CI -0.37 to -0.13, p<0.001). No significant differences were observed between the DES and BMS groups in symptomatic ISR (0% vs 2.9%, p=0.20) or in stroke or death within 30 days or stroke in the target vessel territory between 31 days and 1 year (7.7% vs 12.3%, p=0.45). CONCLUSIONS: Among patients with severe ICAS, treatment with durable fluoropolymer DES resulted in a lower 1-year ISR compared with BMS. TRIAL REGISTRATION NUMBER: NCT05719883.
科研通智能强力驱动
Strongly Powered by AbleSci AI